Yanfen Shi
Overview
Explore the profile of Yanfen Shi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1171
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sun H, Shi Y, Liang D, Liu J, Xu G, Yang X
Indian J Cancer
. 2025 Feb;
61(4):759-765.
PMID: 39960705
Background: Esophageal mixed neuroendocrine-nonneuroendocrine neoplasms (MiNENs) are now known as a neuroendocrine component mixed with a nonneuroendocrine component in a single neoplasm, one of which is in the form of...
2.
Cheng Z, Yu F, Chen R, Cui L, Chen Y, Deng C, et al.
Cancers (Basel)
. 2024 Jul;
16(14).
PMID: 39061142
Background: Thymic neuroendocrine tumors (Th-NETs) are rare and aggressive, with a scarcity of research on predicting patient prognosis. Our study aimed to assess the impact of prognostic markers and temozolomide...
3.
Sahadevan P, Dingar D, Nawaito S, Nair R, Trepanier J, Sahmi F, et al.
Physiol Rep
. 2024 Jun;
12(11):e16108.
PMID: 38872461
ERK3/MAPK6 activates MAP kinase-activated protein kinase (MK)-5 in selected cell types. Male MK5 haplodeficient mice show reduced hypertrophy and attenuated increase in Col1a1 mRNA in response to increased cardiac afterload....
4.
Guo Y, Tian C, Cheng Z, Chen R, Li Y, Su F, et al.
Neuroendocrinology
. 2023 May;
113(9):943-956.
PMID: 37232011
Introduction: Treatment response to the standard therapy is low for metastatic pancreatic neuroendocrine tumors (PanNETs) mainly due to the tumor heterogeneity. We investigated the heterogeneity between primary PanNETs and metastases...
5.
Ferron M, Merlet N, Mihalache-Avram T, Mecteau M, Brand G, Gillis M, et al.
Can J Cardiol
. 2023 Apr;
39(7):952-962.
PMID: 37054880
Background: Polymorphisms in the adenylate cyclase 9 (ADCY9) gene influence the benefits of the cholesteryl ester transfer protein (CETP) modulator dalcetrapib on cardiovascular events after acute coronary syndrome. We hypothesized...
6.
Li Y, Guo Y, Cheng Z, Tian C, Chen Y, Chen R, et al.
Endocr Relat Cancer
. 2023 Jan;
30(9).
PMID: 36645718
The genetic characteristics of rectal neuroendocrine tumors (R-NETs) were poorly understood. Depicting the genetic characteristics may provide a biological basis for prognosis prediction and novel treatment development. Tissues of 18...
7.
Roubille F, Merlet N, Busseuil D, Ferron M, Shi Y, Mihalache-Avram T, et al.
Atheroscler Plus
. 2023 Jan;
45:1-9.
PMID: 36643998
Background And Aims: The anti-inflammatory agent colchicine is gaining interest as a treatment for coronary artery disease. However, the effects of colchicine in atherosclerotic animal models are mostly unknown. This...
8.
Coulis G, Londhe A, Sagabala R, Shi Y, Labbe D, Bergeron A, et al.
Sci Signal
. 2022 Apr;
15(730):eabn6875.
PMID: 35439023
Increased production of reactive oxygen species plays an essential role in the pathogenesis of several diseases, including cardiac hypertrophy. In our search to identify redox-sensitive targets that contribute to redox...
9.
Feng Y, Liu L, Li J, Huang J, Xie J, Menard L, et al.
Oncol Rep
. 2021 Dec;
47(2).
PMID: 34958112
Hepatocellular carcinoma (HCC) is an immunogenic malignancy, which exhibits low responsiveness to programmed cell death protein‑1 (PD‑1)/programmed death ligand‑1 (PD‑L1) antibodies. Therefore, the identification of novel immunotherapeutic targets to treat...
10.
Yuan B, Shi Y, Li Y, Tan H, Jiao P, Su W, et al.
Jpn J Clin Oncol
. 2021 Sep;
51(12):1708-1714.
PMID: 34580725
Background: The pathological classification of well-differentiated pancreatic neuroendocrine tumour (pNET) is based largely upon Ki-67 index. However, current controversies abound about the classification of pNETG1/pNETG2. Patients And Methods: Clinicopathological data...